Thymmune Therapeutics, a Cambridge, MA-based biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, secured $7m in seed financing.
The round was led by Pillar VC, with participation from NYBC Ventures and other investors. Its investor base includes industry pioneers Mark Bamforth, Founder of Brammer Bio and Arranta Bio, James Fordyce, John Maraganore, Ph.D., Former Founding CEO at Alnylam, Judy Pagliuca at PagsGroup, and Philip Reilly, M.D., J.D., along with George Church, Ph.D., who is a scientific advisor to the company.
The company intends to use the funds to advance its lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells, develop its thymic cell engineering platform and expand into additional indications across areas of unmet clinical need in immunology.
Led by Stan Wang, M.D., Ph.D., Founder & CEO, Thymmune is a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company’s approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. Thymmune is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases.
The thymus is a critical organ in the immune system that regulates and develops T cells, which are essential for fighting infection and disease, along with mounting effective responses to vaccines. As part of the natural aging process, the functional thymus begins to shrink and its ability to produce naïve T cells decreases, leading to immune dysfunction and disease.
FinSMEs
01/03/2023